Actionable news
All posts from Actionable news
Actionable news in LPCN: LIPOCINE INC,

Lipocine Announces Presentation Of Lpcn 1021 Clinical Data At 21St Annual Smsna Meeting

The following excerpt is from the company's SEC filing.

Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency or absence of endogenous testosterone ("hypogonadism"), will be presented at the 21st Annual Meeting of the Sexual Medicine Society of North America (SMSNA) in Las Vegas, NV.

Presentation/poster details are as follows:


Dose Titration and Safety of Oral Testosterone (LPCN 102 1) in Hypogonadal Men:

Results from the SOAR Study (#030)

November 20

3:15 pm PST (Poster: 3:00 - 4:00 pm PST)


Mohit Khera, MD

Associate Professor,


Baylor College of Medicine

Houston, TX, US

Director, Laboratory for Andrology Research

Medical Director, Houston Hospital for Specialized Surgery

Assessment of Fasting and Varying Meal Fat Content on the Bioavailability of Testosterone from Oral Testosterone Undecanoate (LPCN 1021) in Hypogonadal Men (#036)

3:45 pm PST (Poster: 3:00 - 4:00 pm PST)

Efficacy and Pharmacokinetics of Oral Testosterone (LPCN 1021) in Hypogonadal Men (#028)

3:05 pm PST (Poster: 3:00 - 4:00 pm PST)

Irwin Goldstein, MD

Director, San Diego Sexual Medicine

Director, Sexual Medicine, Alvarado Hospital, San Diego, CA

Clinical Professor of Surgery, University of California at San Diego

Editor-in-Chief, Sexual Medicine Reviews

President-Elect, International Society for the Study of...